Health Care Innovation
Commentary
Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more
President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow ...
Drug Importation
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Commentary
Import German drug prices to the United States? Nein, danke
President Trump recently issued a blitz of executive orders in an attempt to fulfill his promise to reduce drug prices. One of those orders would put in place a “cure” far worse than the disease. The order in question establishes foreign reference pricing, whereby the federal government ties its reimbursement rates for ...
Drug Pricing
Wayne Winegarden Featured in Newsweek Drug Pricing Story
Title: Big Pharma Backs Joe Biden, But People Don’t Think He’ll Fix Drug Pricing By Darragh Roche Former Vice President Joe Biden is winning the race for donations from Big Pharma but experts and industry stakeholders doubt his plans will successfully lower drug prices or address underlying issues in the ...
Drug Pricing
NEW BRIEF: Mandating that Drug Rebates Benefit Consumers Will Help Patients with High Out-of-Pocket Drug Costs
A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, ...
Commentary
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
Commentary
Trump’s Drug Pricing Order Is A Costly Mistake
On Sunday, September 13, President Trump signed a “most-favored-nation” executive order to reduce U.S. drug prices. It instructs federal officials to set pharmaceutical reimbursements under Medicare Parts B and D equal to the lowest prices paid in other developed countries, including Canada, the United Kingdom, and France. The high cost of medications is a ...
Blog
California Entering Pharmaceutical Business Won’t Lower Drug Prices for Patients
The state of California, which can’t keep the lights on thanks to political interference in energy generation, nor build enough homes because government has poisoned the housing market, is going into the pharmaceutical manufacturing business. But there’s nothing to worry about. If it struggles, taxpayers will be there to bail ...
Health Care
PRI Medical Billing Study Featured in Northern California Record
Title: AB 72 brief analyzes impact of medical billing reform law that’s had bad consequences for patients and practitioners By Sarah Downey, Northern California Record A new policy brief about the impact of California AB 72 finds that the law – designed to alleviate surprise medical billing – while well-intentioned ...
California
Read Revcycle Intelligence Story on Surprise Medical Billing Brief
Surprise Billing Price Controls Decreasing Care Quality in CA By: Jacqueline LaPointe, Reporter Researchers at the Pacific Research Institute are warning Congressmembers to steer clear from price controls as a solution for surprise billing after finding that the policy approach had unintended consequences in California. In a new brief, researchers found ...
Trump wrongly attacks life-saving drug companies on coronavirus vaccines and more
President Trump announced Friday that he will proceed with his plans to peg the prices of certain drugs prescribed largely at doctors’ offices under Medicare Part B to the lower prices that other developed nations pay for those drugs. That may sound good at first glance, but in reality, the move will slow ...
NEW BRIEF: Counterfeit Drugs Harm Patients, Economy, Innovation
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute shows that counterfeit drugs put patients in harm’s way, hinder drug innovation, and lead to job losses. Proposals like drug importation or price controls, if implemented, would exacerbate the problem and ...
Import German drug prices to the United States? Nein, danke
President Trump recently issued a blitz of executive orders in an attempt to fulfill his promise to reduce drug prices. One of those orders would put in place a “cure” far worse than the disease. The order in question establishes foreign reference pricing, whereby the federal government ties its reimbursement rates for ...
Wayne Winegarden Featured in Newsweek Drug Pricing Story
Title: Big Pharma Backs Joe Biden, But People Don’t Think He’ll Fix Drug Pricing By Darragh Roche Former Vice President Joe Biden is winning the race for donations from Big Pharma but experts and industry stakeholders doubt his plans will successfully lower drug prices or address underlying issues in the ...
NEW BRIEF: Mandating that Drug Rebates Benefit Consumers Will Help Patients with High Out-of-Pocket Drug Costs
A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, ...
Price Controls Are Disastrous For Rents And Will Be For Drugs
President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president ...
Trump’s Drug Pricing Order Is A Costly Mistake
On Sunday, September 13, President Trump signed a “most-favored-nation” executive order to reduce U.S. drug prices. It instructs federal officials to set pharmaceutical reimbursements under Medicare Parts B and D equal to the lowest prices paid in other developed countries, including Canada, the United Kingdom, and France. The high cost of medications is a ...
California Entering Pharmaceutical Business Won’t Lower Drug Prices for Patients
The state of California, which can’t keep the lights on thanks to political interference in energy generation, nor build enough homes because government has poisoned the housing market, is going into the pharmaceutical manufacturing business. But there’s nothing to worry about. If it struggles, taxpayers will be there to bail ...
PRI Medical Billing Study Featured in Northern California Record
Title: AB 72 brief analyzes impact of medical billing reform law that’s had bad consequences for patients and practitioners By Sarah Downey, Northern California Record A new policy brief about the impact of California AB 72 finds that the law – designed to alleviate surprise medical billing – while well-intentioned ...
Read Revcycle Intelligence Story on Surprise Medical Billing Brief
Surprise Billing Price Controls Decreasing Care Quality in CA By: Jacqueline LaPointe, Reporter Researchers at the Pacific Research Institute are warning Congressmembers to steer clear from price controls as a solution for surprise billing after finding that the policy approach had unintended consequences in California. In a new brief, researchers found ...
